Go Pro
NYSE:WST

West Pharmaceutical Services (WST) Stock Price, News & Analysis

West Pharmaceutical Services logo
$346.69 -2.73 (-0.78%)
As of 03:58 PM Eastern

About West Pharmaceutical Services Stock (NYSE:WST)

Advanced

Key Stats

Today's Range
$346.43
$350.74
50-Day Range
$319.98
$365.87
52-Week Range
$223.83
$386.00
Volume
282,620 shs
Average Volume
884,232 shs
Market Capitalization
$24.40 billion
P/E Ratio
44.39
Dividend Yield
0.25%
Price Target
$368.08
Consensus Rating
Moderate Buy

Company Overview

West Pharmaceutical Services, Inc. is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle. Its offerings include stoppers and seals, custom-molded polymer parts, prefillable syringe systems and a range of delivery device technologies for self-administration. The company also offers development assistance, analytical testing, regulatory support and contract manufacturing, helping customers take complex parenteral products from design through commercial production while meeting stringent quality and compliance requirements.

West serves a global customer base that includes large pharmaceutical companies, emerging biotech firms and contract development and manufacturing organizations. The company operates manufacturing, research and development, and quality centers across multiple regions to support international supply chains and regulatory markets in North America, Europe, Asia-Pacific and Latin America. With an emphasis on innovation and quality control, West positions itself as a partner for customers seeking reliable containment and delivery solutions for advanced injectable therapies.

AI Generated. May Contain Errors.

West Pharmaceutical Services Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
72nd Percentile Overall Score

WST MarketRank™: 

West Pharmaceutical Services scored higher than 72% of companies evaluated by MarketBeat, and ranked 223rd out of 912 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    West Pharmaceutical Services has received a consensus rating of Moderate Buy. The company's average rating score is 2.87, and is based on 1 strong buy rating, 11 buy ratings, 3 hold ratings, and no sell ratings.

  • Upside/Downside

    The consensus price target for West Pharmaceutical Services is close to its current price, suggesting limited near-term upside or downside.

  • Amount of Analyst Coverage

    West Pharmaceutical Services has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about West Pharmaceutical Services' stock forecast and price target.
  • Earnings Growth

    Earnings for West Pharmaceutical Services are expected to grow by 10.75% in the coming year, from $8.93 to $9.89 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of West Pharmaceutical Services is 44.39, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 39.81.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of West Pharmaceutical Services is 44.39, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 271.41.

  • Price to Earnings Growth Ratio

    West Pharmaceutical Services has a PEG Ratio of 2.44. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    West Pharmaceutical Services has a P/B Ratio of 7.86. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about West Pharmaceutical Services' valuation and earnings.
  • Percentage of Shares Shorted

    3.59% of the float of West Pharmaceutical Services has been sold short.
  • Short Interest Ratio / Days to Cover

    West Pharmaceutical Services has a short interest ratio ("days to cover") of 2.54, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in West Pharmaceutical Services has recently increased by 6.38%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    West Pharmaceutical Services has a dividend yield of 0.25%, which is in the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    West Pharmaceutical Services does not have a long track record of dividend growth.

  • Dividend Coverage

    The dividend payout ratio of West Pharmaceutical Services is 11.27%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Dividend Sustainability

    Based on earnings estimates, West Pharmaceutical Services will have a dividend payout ratio of 8.90% next year. This indicates that West Pharmaceutical Services will be able to sustain or increase its dividend.

  • Read more about West Pharmaceutical Services' dividend.
  • News Sentiment

    West Pharmaceutical Services has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 17 news articles for West Pharmaceutical Services this week, compared to 6 articles on an average week.
  • Search Interest

    9 people have searched for WST on MarketBeat in the last 30 days. This is an increase of 800% compared to the previous 30 days.
  • MarketBeat Follows

    9 people have added West Pharmaceutical Services to their MarketBeat watchlist in the last 30 days. This is an increase of 800% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, West Pharmaceutical Services insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    0.60% of the stock of West Pharmaceutical Services is held by insiders.

  • Percentage Held by Institutions

    93.90% of the stock of West Pharmaceutical Services is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about West Pharmaceutical Services' insider trading history.
Receive WST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for West Pharmaceutical Services and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

WST Stock News Headlines

What is Zacks Research's Forecast for WST Q3 Earnings?
Ticker Revealed: Pre-IPO Access to "Next Elon Musk" Company
We’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.tc pixel
See More Headlines

WST Stock Analysis - Frequently Asked Questions

West Pharmaceutical Services' stock was trading at $275.53 at the beginning of the year. Since then, WST stock has increased by 25.8% and is now trading at $346.69.

West Pharmaceutical Services, Inc. (NYSE:WST) released its quarterly earnings data on Thursday, July, 23rd. The medical instruments supplier reported $2.37 earnings per share for the quarter, beating the consensus estimate of $2.08 by $0.29. The firm's revenue was up 13.8% compared to the same quarter last year.
Read the conference call transcript
.

West Pharmaceutical Services' Board of Directors approved a stock buyback program on Tuesday, February 17th 2026, which authorizes the company to repurchase $1,000,000,000 in outstanding shares, according to EventVestor. This means that the company could purchase up to 5.6% of its shares through open market purchases. Shares buyback programs are usually an indication that the company's management believes its shares are undervalued.

West Pharmaceutical Services subsidiaries include Drug Delivery Assets From Plastef Investissements SA, Medimop Medical Projects Ltd., The Tech Group Inc., Tech Group Europe Limited (dba West), Tech Group Grand Rapids Inc. (dba West), TGPR Holdings Limited, WD SG Pte. Ltd., and others.

West Pharmaceutical Services' top institutional shareholders include BlackRock Inc. (9.45%), Bank of New York Mellon Corp (2.90%), Generation Investment Management LLP (2.88%) and Findlay Park Partners LLP (0.85%). Insiders that own company stock include Eric Mark Green, Thomas W Hofmann, Annette F Favorite, Cindy Reiss-Clark, Silji Abraham, Chad Winters and Charles Witherspoon.
View institutional ownership trends
.

Shares of WST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that West Pharmaceutical Services investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Home Depot (HD), Chevron (CVX) and Netflix (NFLX).

Company Calendar

Last Earnings
7/23/2026
Record date for 8/5 Dividend
7/29/2026
Ex-Dividend for 8/5 Dividend
7/29/2026
Dividend Payable
8/05/2026
Today
8/17/2026
Next Earnings (Estimated)
10/22/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Healthcare Equipment & Supplies
Sub-Industry
Healthcare Supplies
Current Symbol
NYSE:WST
CIK
105770
Employees
10,800
Year Founded
1923

Price Target and Rating

High Price Target
$447.00
Low Price Target
$295.00
Potential Upside/Downside
+6.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.87
Research Coverage
15 Analysts

Profitability

EPS (Trailing Twelve Months)
$7.81
Trailing P/E Ratio
44.39
Forward P/E Ratio
38.82
P/E Growth
2.44
Net Income
$493.70 million
Net Margins
16.98%
Pretax Margin
20.85%
Return on Equity
20.11%
Return on Assets
14.83%

Debt

Debt-to-Equity Ratio
0.07
Current Ratio
2.82
Quick Ratio
2.12

Sales & Book Value

Annual Sales
$3.07 billion
Price / Sales
7.94
Cash Flow
$9.66 per share
Price / Cash Flow
35.88
Book Value
$44.10 per share
Price / Book
7.86

Miscellaneous

Outstanding Shares
70,380,000
Free Float
69,954,000
Market Cap
$24.40 billion
Optionable
Optionable
Beta
1.15

Social Links

7 Stocks That Will Be Magnificent in 2026 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NYSE:WST) was last updated on 8/17/2026 by MarketBeat.com Staff.
From Our Partners